Mouse studies have revealed more about the mechanisms behind cancer drugs in trials

Grace Li                                                                                                            December 2nd, 2018
A protein crucial for cell division may help to explain why certain cancer therapies are more effective in some patients than others. Genetically altered regulation of this protein has helped A*STAR researchers better understand the mechanisms underpinning new cancer therapies that target the same regulatory process. Cyclin-dependent kinase 1 (CDK1) is necessary for cell division; its absence causes death during embryonic development. However, elevated CDK1 activity is a feature of all cancers, and drives the cell proliferation required for tumor growth. Consequently, CDK1 activity is tightly regulated in vivo.
See original article at:



登錄 X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.